Clinical and pathologic characteristics of breast cancers determined to be HER2-positive by fluorescence in-situ hybridization (FISH) using alternative chromosome 17 probes

被引：0
|
作者：
Desai, Neelam V. [1 ]
Torous, Vanda [1 ]
Cruz, Cassandra [1 ]
Schnitt, Stuart J. [1 ]
Tung, Nadine [1 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-09-25
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes
    Blanton, Kristen C.
    Deal, Allison M.
    Kaiser-Rogers, Kathleen A.
    Anders, Carey K.
    O'Connor, Siobhan M.
    Hertel, Johann D.
    Calhoun, Benjamin C.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2020, 48
  • [2] HER2 FISH results in breast cancers with increased cen17 signals using alternative chromosome 17 probes reclassifying unveils HER2-positive specimens within the equivocal category
    Brockhoff, G.
    Holzschuh, M. -A.
    Hauke, S.
    Inwald, E.
    Czyz, Z.
    Polzer, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 116 - 116
  • [3] Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay
    Neelam V. Desai
    Vanda Torous
    Joel Parker
    James T. Auman
    Gary B. Rosson
    Cassandra Cruz
    Charles M. Perou
    Stuart J. Schnitt
    Nadine Tung
    Breast Cancer Research, 20
  • [4] Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay
    Desai, Neelam V.
    Torous, Vanda
    Parker, Joel
    Auman, James T.
    Rosson, Gary B.
    Cruz, Cassandra
    Perou, Charles M.
    Schnitt, Stuart J.
    Tung, Nadine
    BREAST CANCER RESEARCH, 2018, 20
  • [5] Resolving HER2 Status in Breast Carcinoma Patients with Complete Deletion of Chromosome 17 Centromere (CEP17) in Fluorescence In-Situ Hybridization (FISH) Assays
    Wilcock, Diane
    Zhao, Jian
    Anderson, Erica
    Coleman, Joshua
    Gulbahce, H. Evin
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [6] The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer
    Xu, Zhigao
    Xu, Peipei
    Fan, Wei
    Huang, Ben
    Cheng, Qingyuan
    Zhang, Zheng
    Wang, Ping
    Yu, Mingxia
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (03) : 2095 - 2103
  • [7] Cytogenetic Alterations in Her2/Neu Gene (HER2) and Chromosome 17 (chr17) by Fluorescent In-Situ Hybridization (FISH) in Immunohistochemically (IHC) Equivocal (2+) Breast Cancers
    Chitale, D. A.
    Sanchez, J.
    Adeyinka, A.
    LABORATORY INVESTIGATION, 2011, 91 : 32A - 32A
  • [8] HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category
    Holzschuh, Maria-Anna
    Czyz, Zbigniew
    Hauke, Sven
    Inwald, Elisabeth C.
    Polzer, Bernhard
    Brockhoff, Gero
    HISTOPATHOLOGY, 2017, 71 (04) : 610 - 625
  • [9] Comparison of HER-2/NEU amplification using fluorescent in situ hybridization (FISH) with immunohistochemically determined overexpression in breast cancers
    Nelson, DL
    Potts, SA
    Bromley, C
    Pou, B
    Raab, SS
    Thomas, PA
    LABORATORY INVESTIGATION, 1996, 74 (01) : 106 - 106
  • [10] Cytogenetic Alterations in Her2/Neu Gene (HER2) and Chromosome 17 (chr17) by Fluorescent In-Situ Hybridization (FISH) in Immunohistochemically (IHC) Equivocal (2+) Breast Cancers.
    Chitale, D. A.
    Sanchez, J.
    Adeyinka, A.
    MODERN PATHOLOGY, 2011, 24 : 32A - 32A
12345